Intranasal delivery of VEGF enhances compensatory lung growth in mice
Open Access
- 7 June 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (6) , e0198700
Abstract
Vascular endothelial growth factor (VEGF) has previously been demonstrated to accelerate compensatory lung growth (CLG) in mice and may be a useful therapy for pulmonary hypoplasia. Systemic administration of VEGF can result in side effects such as hypotension and edema. The aim of this study was to explore nasal delivery as a route for intrapulmonary VEGF administration. Eight-week-old C57BL/6 male mice underwent left pneumonectomy, followed by daily nasal instillation of VEGF at 0.5 mg/kg or isovolumetric saline. Lung volume measurement, morphometric analysis, and protein expression studies were performed on lung tissues harvested on postoperative day (POD) 4. To understand the mechanism by which VEGF accelerates lung growth, proliferation of human bronchial epithelial cells (HBEC) was assessed in a co-culture model with lung microvascular endothelial cells (HMVEC-L) treated with and without VEGF (10 ng/mL). The assay was then repeated with a heparin-binding EGF-like growth factor (HB-EGF) neutralizing antibody ranging from 0.5–50 μg/mL. Compared to control mice, the VEGF-treated group displayed significantly higher lung volume (P = 0.001) and alveolar count (P = 0.005) on POD 4. VEGF treatment resulted in increased pulmonary expression of HB-EGF (P = 0.02). VEGF-treated HMVEC-L increased HBEC proliferation (P = 0.002) while the addition of an HB-EGF neutralizing antibody at 5 and 50 μg/mL abolished this effect (P = 0.01 and 0.002, respectively). These findings demonstrate that nasal delivery of VEGF enhanced CLG. These effects could be mediated by a paracrine mechanism through upregulation of HB-EGF, an epithelial cell mitogen.Keywords
Funding Information
- National Institutes of Health (1F32DK104525)
- National Institutes of Health (5T32HL007734)
- National Institutes of Health (5T32HL007734)
- National Institutes of Health (4T35HL110843)
This publication has 54 references indexed in Scilit:
- Vascular endothelial growth factor accelerates compensatory lung growth by increasing the alveolar unitsPediatric Research, 2018
- Quantitative microscopy of the lung: a problem-based approach. Part 2: stereological parameters and study designs in various diseases of the respiratory tractAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2013
- VEGF increases the proliferative capacity and eNOS/NO levels of endothelial progenitor cells through the calcineurin/NFAT signalling pathwayCell Biology International, 2012
- Heparin-Binding EGF-Like Growth Factor Promotes Intestinal Anastomotic HealingJournal of Surgical Research, 2011
- Endothelial-Derived Angiocrine Signals Induce and Sustain Regenerative Lung AlveolarizationCell, 2011
- Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung InjuryCirculation, 2005
- Inhibition of angiogenesis decreases alveolarization in the developing rat lungAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2000
- VEGF Improves Myocardial Blood Flow but Produces EDRF-Mediated Hypotension in Porcine HeartsJournal of Surgical Research, 1996
- Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalationEnvironmental Research, 1976
- A principle for counting tissue structures on random sectionsJournal of Applied Physiology, 1962